2018•Leukemia & lymphoma/Leukemia and lymphomaRequires access

Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

Antonio Rueda, Virginia Calvo, María Casanova, Delvys Rodríguez‐Abreu, David Aguiar, Marta Llanos, Ruth Álvarez, Natividad Martínez-Banaclocha, Jesús Alfaro, Cristina Quero, Ana Blasco, Luis de la Cruz‐Merino, Joaquín Herrero, Francisco R. García-Arroyo, Mariano Provencio

Open publisher page 0 citations

Abstract

Bendamustine is a drug widely used in the treatment of follicular lymphoma. Although it was initially approved as monotherapy in patients refractory to rituximab [1], better results were obtained w...

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Bendamustine, Rituximab, Follicular lymphoma, Medicine, Internal medicine, Oncology, Refractory (planetary science), Lymphoma